18277522. COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES simplified abstract (The Regents of the University of California)

COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES

Organization Name

The Regents of the University of California

Inventor(s)

Daniel H. Geschwind of Los Angeles CA (US)

Michael E. Jung of Los Angeles CA (US)

Liting Deng of Los Angeles CA (US)

Flora Hinz of Los Angeles CA (US)

Jennifer M. Murphy of Los Angeles CA (US)

Gaoyuan Ma of Los Angeles CA (US)

Robert Damoiseaux of Los Angeles CA (US)

COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES - A simplified explanation of the abstract

This abstract first appeared for US patent application 18277522 titled 'COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES

Simplified Explanation

The patent application discloses compounds and methods for treating tauopathy, a condition characterized by the accumulation of tau protein in the brain.

• Compounds and methods for treating tauopathy are disclosed in the patent application.
• Tauopathy is a condition characterized by the accumulation of tau protein in the brain.

Potential Applications

The technology could potentially be applied in the development of new drugs for the treatment of tauopathy and related neurodegenerative diseases.

Problems Solved

This technology addresses the need for effective treatments for tauopathy, a condition that currently has limited therapeutic options available.

Benefits

The compounds and methods disclosed in the patent application have the potential to improve the quality of life for patients suffering from tauopathy by targeting the underlying cause of the disease.

Potential Commercial Applications

The technology could have commercial applications in the pharmaceutical industry for the development of novel therapeutics for tauopathy and other tau-related disorders.

Possible Prior Art

Prior research may have explored various compounds and methods for treating tauopathy, but the specific compounds and methods disclosed in this patent application may offer unique advantages or improvements over existing approaches.

How does this technology compare to existing treatments for tauopathy?

The article does not provide a direct comparison between the compounds and methods disclosed in the patent application and existing treatments for tauopathy.

What are the potential side effects of the compounds described in the patent application?

The article does not address the potential side effects or safety profile of the compounds disclosed in the patent application.

Original Abstract Submitted

Disclosed are compounds and methods for treating tauopathy.